{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:03:30Z","timestamp":1760043810814},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,6,9]],"date-time":"2006-06-09T00:00:00Z","timestamp":1149811200000},"content-version":"vor","delay-in-days":830,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction Biology"],"published-print":{"date-parts":[[2004,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to profile and compare blood naltrexone and 6\u2010 \u03b2\u2010 naltrexol levels with time following treatment with two sustained\u2010release naltrexone preparations produced by GoMedical Industries, Australia at a community heroin treatment clinic in Perth, Western Australia. A sample of 10 patients who each received a 1.7 g naltrexone implant were compared to 24 patients who each received a 3.4 g naltrexone implant as treatment for heroin dependence. Blood naltrexone levels following treatment with the 1.7 g naltrexone implant remained above 2 and 1 ng\/ml for approximately 90 and 136 days, respectively. Use of the 3.4 g naltrexone implant extended the period of coverage to approximately 297 (1 ng\/ml) or 188 (2 ng\/ml) days. Blood 6\u2010 \u03b2 \u2010naltrexol levels remained above 10 ng\/ml for approximately 18 and 83 days, respectively, following use of the 1.7 g and 3.4 g naltrexone implants. The current study data indicate that blood naltrexone and 6 \u2010\u03b2\u2010 naltrexol levels following treatment with either the 1.7 g or 3.4 g naltrexone implant are greater than those reported in other published data on other sustained\u2010release naltrexone preparations. Furthermore, duration of blood naltrexone and 6 \u2010\u03b2\u2010 naltrexol levels achieved following use of the 3.4 g implant were superior to those achieved with the 1.7 g naltrexone implant, with naltrexone blood levels maintained above 2 ng\/ml for a period of approximately 6.3 months compared to 3 months, respectively. The implications of this in managing the heroin\u2010dependent patient, especially those who find it difficult to shift away from dependent use patterns, are discussed.<\/jats:p>","DOI":"10.1080\/13556210410001674103","type":"journal-article","created":{"date-parts":[[2004,4,21]],"date-time":"2004-04-21T14:29:37Z","timestamp":1082557777000},"page":"59-65","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Blood naltrexone and 6\u2010\u00df\u2010naltrexol levels following naltrexone implant: comparing two naltrexone implants"],"prefix":"10.1111","volume":"9","author":[{"given":"GK","family":"Hulse","sequence":"first","affiliation":[]},{"given":"DE","family":"Arnold\u2010Reed","sequence":"additional","affiliation":[]},{"given":"G","family":"O'Neil","sequence":"additional","affiliation":[]},{"given":"C\u2010T","family":"Chan","sequence":"additional","affiliation":[]},{"given":"R","family":"Hansson","sequence":"additional","affiliation":[]},{"given":"P","family":"O'Neil","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2006,6,9]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"5","volume-title":"naltrexone. NIDA Research Monograph","author":"Julius D","year":"1976"},{"key":"e_1_2_1_3_2","first-page":"42","article-title":"Clinical experience with naltrexone in suburban opioid addicts","volume":"45","author":"Tennant FS","year":"1984","journal-title":"J Clin Psychiatr"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1991.tb01859.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/09595230096138"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0160-3450(16)31736-6"},{"key":"e_1_2_1_7_2","first-page":"260","article-title":"Naltrexone implants for opiate addiction: new life for a middle aged drug","volume":"267","author":"Brewer C","year":"2001","journal-title":"Pharm J"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/13556210220139541"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130100909"},{"key":"e_1_2_1_10_2","volume-title":"Determination of naltrexone and 6\u2010\u03b2\u2010naltrexol in human plasma by LC\u2010MS\u2010MS","author":"Bugge CJL","year":"1996"},{"key":"e_1_2_1_11_2","first-page":"536","article-title":"Death as a complication of ultrarapid opioid detoxification (UROD)","volume":"38","author":"Olmedo RE","year":"2000","journal-title":"J Toxicol Clin Toxico"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976203315"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(94)90161-9"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(85)90076-6"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00098-2"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198835030-00002"},{"key":"e_1_2_1_17_2","first-page":"960","article-title":"Letter to the editor","volume":"9","author":"O'Neil G","year":"2002","journal-title":"Acad Emerg Me"}],"container-title":["Addiction Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1080%2F13556210410001674103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/13556210410001674103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T21:54:30Z","timestamp":1700171670000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/13556210410001674103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["10.1080\/13556210410001674103"],"URL":"https:\/\/doi.org\/10.1080\/13556210410001674103","archive":["Portico"],"relation":{},"ISSN":["1355-6215","1369-1600"],"issn-type":[{"value":"1355-6215","type":"print"},{"value":"1369-1600","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]},"assertion":[{"value":"2006-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}